These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626 [TBL] [Abstract][Full Text] [Related]
3. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307 [TBL] [Abstract][Full Text] [Related]
4. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial. Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851 [TBL] [Abstract][Full Text] [Related]
5. Rapid switching between transdermal fentanyl and methadone in cancer patients. Mercadante S; Ferrera P; Villari P; Casuccio A J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965 [TBL] [Abstract][Full Text] [Related]
6. Comparison of TTS-fentanyl with sustained-release oral morphine in the treatment of patients not using opioids for mild-to-moderate pain. van Seventer R; Smit JM; Schipper RM; Wicks MA; Zuurmond WW Curr Med Res Opin; 2003; 19(6):457-69. PubMed ID: 14594516 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Clark AJ; Ahmedzai SH; Allan LG; Camacho F; Horbay GL; Richarz U; Simpson K Curr Med Res Opin; 2004 Sep; 20(9):1419-28. PubMed ID: 15383190 [TBL] [Abstract][Full Text] [Related]
8. Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. Bruera E; Palmer JL; Bosnjak S; Rico MA; Moyano J; Sweeney C; Strasser F; Willey J; Bertolino M; Mathias C; Spruyt O; Fisch MJ J Clin Oncol; 2004 Jan; 22(1):185-92. PubMed ID: 14701781 [TBL] [Abstract][Full Text] [Related]
9. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Sittl R; Likar R; Nautrup BP Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486 [TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159 [TBL] [Abstract][Full Text] [Related]
11. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Tawfik MO; Bryuzgin V; Kourteva G; Curr Med Res Opin; 2004 Mar; 20(3):259-67. PubMed ID: 15025835 [TBL] [Abstract][Full Text] [Related]
12. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298 [TBL] [Abstract][Full Text] [Related]
13. Early conversion from oral morphine to transdermal fentanyl in patients with cancer pain. Tani M; Fuku A; Terashita S; Kashiwagi H; Yukawa H; Yamaue H Hepatogastroenterology; 2008; 55(86-87):1545-8. PubMed ID: 19102339 [TBL] [Abstract][Full Text] [Related]
14. [Usefulness of fentanyl patch (Durotep) in cancer patients when rotated from morphine preparations]. Akiyama Y; Iseki M; Izawa R; Ishii K; Miyazaki T; Yamaguchi S; Tani Y Masui; 2007 Mar; 56(3):317-23. PubMed ID: 17366919 [TBL] [Abstract][Full Text] [Related]
15. Improved cancer pain treatment using combined fentanyl-TTS and tramadol. Marinangeli F; Ciccozzi A; Aloisio L; Colangeli A; Paladini A; Bajocco C; Coaccioli S; Varrassi G Pain Pract; 2007 Dec; 7(4):307-12. PubMed ID: 17986161 [TBL] [Abstract][Full Text] [Related]
16. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids. Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396 [TBL] [Abstract][Full Text] [Related]
17. [The opioid combination of transdermal fentanyl and sustained release morphine for refractory cancer pain--a case report]. Shinjo T; Okada M Gan To Kagaku Ryoho; 2005 Nov; 32(12):1997-2000. PubMed ID: 16282744 [TBL] [Abstract][Full Text] [Related]
18. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130 [TBL] [Abstract][Full Text] [Related]
19. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Lawlor PG; Turner KS; Hanson J; Bruera ED Cancer; 1998 Mar; 82(6):1167-73. PubMed ID: 9506365 [TBL] [Abstract][Full Text] [Related]
20. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone. Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]